Andrew Espejo has been announced as special honouree at the launch of the Life Science 50 edition of Business & Finance, taking place at the Royal College of Physicians, Kildare Street, Dublin 2.
The total life science sector, across medical devices, pharma and bio in Ireland exports more than €45bn annually, employs over 50,000 people directly and includes operations of six of the top seven diagnostics companies.
Business & Finance are delighted to announce that Andrew Espejo of Bristol-Myers Squibb (BMS) will be the special honouree at the event on July 13th.
Espejo joined BMS in 2012 as general manager of the former of Bristol-Myers Squibb (BMS) Mount Vernon facility. Prior to BMS, Espejo held roles of increased responsibility in the pharmaceutical industry, which has provided him with a well-rounded view of manufacturing and operations.
In March of this year he was appointed general manager, active pharmaceutical ingredients (API) operations at the company’s facility in Swords, Co. Dublin.
Espejo’s distinguished background of successfully propelling quality programmes and initiatives that spur operational growth and profitability is unquestionable. He is an exceptional communicator with strong negotiation, problem resolution and client needs assessment aptitude.
He holds a BS and an MS in Mechanical Engineering from Manhattan College.
Guest speaker on the night will be John O’Connor, head of Multinationals at HSBC, title sponsors of the event. O’Connor manages a dedicated team to service subsidiaries of international companies with significant operations in Ireland with regional responsibilities across Europe, Middle East, Asia and Africa.
HSBC is one of the strongest credit rated banks operating in Ireland with a significant international reach in to 80 countries worldwide.
The company has full banking operations in Ireland from its Dublin office, which includes treasury, FX, and commodities management, trade and receivables finance and payments cash management.
Miriam Kennedy, head of Business Tourism with Fáilte Ireland explaines why the tourism body was partnering with the Business & Finance Life Science 50 edition and event. “This publication – and access to its influential readers – offers Fáilte Ireland a valuable opportunity to raise awareness about our Conference Ambassador Programme and how we can support Irish scientists, researchers and medical science ‘ambassadors’ to bring their international colleagues and peers to Ireland for an international conference.”
Kennedy continues: “We are fortunate as a country to have so many talented and internationally influential medical and scientific leaders who have in the past championed Ireland and won prestigious international conferences to these shores. We look forward to working with many more such champions in the future.”
PIPELINE OF TALENT
Judith Moffett, director of Life Science 50 event partner Cpl, comments: “The life sciences industry journey and growth in Ireland has been exponential, starting with humble beginnings in the 1960s, to Ireland being a global leader in life sciences in the 21st century, with 25,000 people directly employed in this sector and Ireland being the seventh-largest exporter of life sciences products.
She continues: “The sourcing and pipelining of talent is critical to maintaining Ireland’s unique status in the life sciences sector. At Cpl, we are passionate in bridging the gap in talent for our life sciences clients. Cpl Science and Engineering is a global life sciences recruitment industry expert and our team in Ireland, is the largest, dedicated life sciences team.
“Cpl Science and Engineering is delighted and honoured to partner with the Business & Finance Life Science 50 edition to recognise the unique innovators in the sector.”
The sourcing and pipelining of talent is critical to maintaining Ireland’s unique status in the life sciences sector
SUPPORT AND COLLABORATION
Michael Finn, health and life sciences partner at event partner Matheson, highlights the importance of the sector. “The Matheson life sciences group advises organisations in the pharmaceutical, biotechnology, medical technology, agri-chem and healthcare sectors on the full range of legal issues that affect them,” says Finn.
“In Ireland, the level of support and collaboration for start-up, emerging or expanding companies, and the level of support and collaboration between industry, academia and the Irish Government makes Ireland one of the most attractive places for pharmaceutical and medtech companies to conduct their business.”
For more information about the event, contact Noelle Campbell:
Tel: +353 87 978 1764